Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Human Genome Epidemiology Literature Finder|Home|PHGKB

Human Genome Epidemiology Literature Finder


Last data update: Jan 25, 2025. (Total: 235671Documents)
   dataset        GWAS Only
Filtered By:

Previous    

Records 1 - 10 (of 10 Records)

Query Trace: Tuberculosis and meta-analysis and NAT2[original query]
Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2008 Sep 12 (9): 994-1002.
Sun F, Chen Y, Xiang Y, Zhan
NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2012 May 16 (5): 589-95.
Wang P-Y, Xie S-Y, Hao Q, Zhang C, Jiang B
The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2014 Jun 24 34-40.
Sheng Yun-Jian, Wu Gang, He Hong-Yan, Chen Wen, Zou Yong-Sheng, Li Qin, Zhong Li, Huang Yong-Mao, Deng Cun-Lia
The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
British journal of clinical pharmacology 2018 Jul .
Zhang Min, Wang Shuqiang, Wilffert Bob, Tong Rongsheng, van Soolingen Dick, van den Hof Susan, Alffenaar Jan-Will
NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis.
Pharmacogenetics and genomics 2018 Jul 28 (7): 167-176.
Suvichapanich Supharat, Fukunaga Koya, Zahroh Hilyatuz, Mushiroda Taisei, Mahasirimongkol Surakameth, Toyo-Oka Licht, Chaikledkaew Usa, Jittikoon Jiraphun, Yuliwulandari Rika, Yanai Hideki, Wattanapokayakit Sukanya, Tokunaga Katsus
Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence.
Bioscience reports 2018 12 39 (1): .
Khan Saif, Mandal Raju K, Elasbali Abdulbaset Mohamed, Dar Sajad A, Jawed Arshad, Wahid Mohd, Mahto Harishankar, Lohani Mohtashim, Mishra Bhartendu Nath, Akhter Naseem, Rabaan Ali A, Haque Shafi
Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis.
BMJ open 2019 Aug 9 (8): e027940.
Yang Seungwon, Hwang Se Jung, Park Jung Yun, Chung Eun Kyoung, Lee Jangik
NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2019 3 23 (3): 293-305.
Richardson M, Kirkham J, Dwan K, Sloan D J, Davies G, Jorgensen A
A Systematic Review and Meta-analysis of Isoniazid Pharmacokinetics in Healthy Volunteers and Patients with Tuberculosis.
Clinical therapeutics 2020 Oct .
Hong Boi-Lam, D'Cunha Ronilda, Li Peizhi, Al-Shaer Mohammad H, Alghamdi Wael A, An Guohua, Peloquin Charl
Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.
BMC genomic data 2024 12 25 (1): 103.
Rashmi Mahajan, Anuj Kumar Tya
TOP